Introduction

Cystic fibrosis is one of the most common life-threatening autosomal recessive disorders that is usually estimated to affect 1 in 2000–3000 Caucasian newborns, with a carrier frequency of 1 in 26 individuals (1). In its classic and most common form, cystic fibrosis manifests with chronic obstructive lung disease, exocrine pancreatic insufficiency, elevated sweat chloride concentration and in males infertility due to obstructive azoospermia (2).

Cystic fibrosis is caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, spanning 250kb at chromosomal region 7q31.3 and consisting of 27 exons. The gene was discovered in 1989, and it encodes a protein expressed at the apical membrane of exocrine epithelial cells (3). CFTR protein functions principally as a cAMP-induced chloride channel and appears capable of regulating other ion channels.

The most common mutation in the CFTR gene is F508del located in exon 10, and it is present on approximately two-thirds (66%) of all cystic fibrosis chromosomes. However, there is great mutational heterogeneity in the remaining one-third of all alleles. Nearly 1300 mutations within CFTR have been identified to date, and reported to Cystic Fibrosis Genetic Analysis Consortium (4). Although these mutations vary greatly in their frequency and distribution, the vast majority are present in either single individual or small number of individuals.

Mutations affect CFTR through a variety of molecular mechanisms which can produce little or no functional CFTR at the apical membrane. The phenotypic spectrum associated with mutations in the CFTR gene extends beyond the classically defined cystic fibrosis. Besides patients with atypical cystic fibrosis, there are large numbers of so-called monosymptomatic diseases, such as various forms of obstructive azoospermia, idiopathic pancreatitis or disseminated bronchiectasis associated with CFTR mutations uncharacteristic for cystic fibrosis (5).
This paper reports a case of atypical cystic fibrosis that was diagnosed by the combination of direct and indirect mutation detection methods. It is shown that the patient is a compound heterozygote for two CFTR mutations.

**Materials and Methods**

**Case history**

Patient is a 38 year-old woman presented with a diagnosis of bronchiectasis. Her past medical history was noteworthy for the onset of respiratory symptoms such as: recurrent pneumonia and periods of cough and haemoptysis. Sweat test performed at the age of 6 showed borderline values. At the age of 33, computed tomography (CT) has shown the presence of bronchiectasis. At the age of 38, she presented with lung disease progression, which was observed by CT, and was referred for molecular testing for cystic fibrosis.

**Methods**

DNA was extracted from peripheral blood using GFX\textsuperscript{TM} Genomic Blood DNA Purification Kit (Amersham Biosciences).

The presence of the most frequent CFTR mutation – F508del was detected by PCR-Mediated Site-Directed Mutagenesis (PSM) method (6). The 219bp long fragment was amplified with the following primers: 5'-GCACCATTAAAGAAAATATGAT-3' and 5'-CATTCACAGTAGCTTACCCA-3', and digested with MboI. Products were analyzed on 10% polyacrilamide gel.

The screening for the presence of variations in CFTR exons was performed by Denaturing Gradient Gel Electrophoresis (DGGE) method, as previously described (7). Exon 18 was amplified with the following primers: 5'-GTAGATGCTGTGATGAACTG-3' and 5'-GTGGCTATCTATGAGAAGGA-3' and sequenced with the primer 5'-TGCCCTAGGAGAAGTGTG-3' using Thermo Sequenase Cy5 Dye Terminator Kit (Amersham Pharmacia Biotech).

**Results and Discussion**

The presence of CFTR F508del mutation was analyzed by PSM method. After digestion with MboI normal allele is digested giving fragments 202bp and 17bp long, while mutant allele remains undigested. This analysis has shown that the patient is heterozygous for F508del mutation (Figure 1).

The screening for the second mutation was performed using DGGE. After DGGE analysis was performed for several CFTR exons, altered band pattern was seen in exon 18. Mixing of the patient sample with control samples heterozygous for two mutations in exon 18, has shown that the mutation present in patient's sample is D1152H. Mixing with M1137V/N control gives extra heteroduplex bands, while no extra bands are seen after mixing with D1152H/N control (Figure 2).

The presence of D1152H mutation was confirmed by direct DNA sequencing (Figure 3).
The described patient, presenting with atypical cystic fibrosis, was found to be compound heterozygote for two CFTR mutations, F508del and D1152H. It has been previously reported that the F508del/D1152H genotype is associated with mild CF phenotype (8).

The CFTR mutation D1152H is caused by point mutation G to C at position 3586. Patients carrying D1152H mutation are usually diagnosed at advanced age, present mild pulmonary disease and pancreatic sufficiency. The mutation D1152H was found to be associated with normal sweat chloride values (9). Characterization at the protein and at the electrophysiological level has shown that this mutation does not alter the permeability sequence of the CFTR channels (10). However, it significantly reduces the whole cell cAMP activated chloride currents, indicating that this mutation interferes with the proper gating of the chloride channels.

In vast majority of cases, the sweat test remains the essential diagnostic tool for establishing the diagnosis of CF. Although the threshold of 60 mmol/L for the sweat chloride concentration has proven to be discriminating and useful in clinical practice, in described patient a borderline value was observed. Only after the molecular genetic testing, the diagnosis of cystic fibrosis was confirmed. In our opinion in borderline sweat chloride results, clinician should consider molecular genetics testing for cystic fibrosis. Further exhaustive genetic analysis is justified in patients with symptoms suggestive of CF and borderline sweat chloride concentration.

Although methods for direct detection of the most frequent CFTR mutations remain essential, methods for the screening of the whole gene are increasingly used for the purposes of cystic fibrosis molecular diagnostics. In our experience, the denaturing gradient gel electrophoresis is a method of choice, due to its reliability and sensitivity. It is followed by direct DNA sequencing, used for characterization of the detected aberrant pattern. The strategy of mutation detection in analysis of CF patients, especially those with atypical presentations who carry less frequent mutations, should include both direct and indirect methods of molecular diagnostics.

ANALIZA CFTR GENA KOD PACIJENATA SA ATIPIČNOM CISTIČNOM FIBROZOM

Aleksandra Nikolić1, Aleksandra Đivac1, Nada Bogdanović2, Marija Mitić-Milikic2, Dragica Radojković1

1Institut za molekularnu genetiku i genetičko inženjerstvo, Beograd
2Institut za plućne bolesti i tuberkulozu, Klinički centar Srbije, Beograd


Ključne reči: atipična cistična fibroza, CFTR gen, DGGE, molekularna dijagnostika

References
7. Fanen P, Ghanem N, Vidaud M, Besmond C, Martin J, Costes B et al. Molecular characterization of cystic fibrosis: 16 novel mutations identified by analysis of the whole Cystic Fibrosis Conductance Transmembrane Regu-


Received: March 19, 2004

Accepted: August 5, 2004